此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Multicenter Prospective Study Protocol for Validating Surgical Quality Standards in D3 Lymphadenectomy for Oncological Right Hemicolectomy (D3L)

2026年9月29日 更新者:Sebastian Jeri、Fundació d'investigació Sanitària de les Illes Balears

Introduction: D3 lymphadenectomy (D3L) for right hemicolectomy, proposed by Eastern guidelines, aims to improve oncological outcomes by extending resection to include lymphatic drainage zones beyond those addressed by complete mesocolic excision (CME). However, the absence of standardized anatomopathological quality parameters limits its validation. This multicenter study seeks to validate this criteria, including the "right mesocolic sail," to classify D3L specimens and evaluate its clinical and oncological implications.

Materials and Methods: This prospective, multicenter study involves 11 hospitals in Spain. Surgical specimens from right hemicolectomy with D3L will be analyzed for the presence of the "right mesocolic sail" and classified as complete or incomplete D3L. Standard CME criteria will also be applied. Patient data, surgical details, and oncological outcomes at 3 and 5 years will be collected. Statistical analysis will compare lymph node retrieval, recurrence rates, survival outcomes, and perioperative complications between groups.

Results: The study will validate the right mesocolic sail as a quality parameter for D3L. Preliminary data from prior phases confirm increased lymph node retrieval and the presence of positive nodes in D3L specimens. Additional analyses will determine the impact of D3L on recurrence rates, survival, and perioperative risks.

Discussion: This study aims to provide standardized anatomopathological criteria to evaluate D3L, facilitating comparative studies and addressing its controversial oncological benefits. If validated, the criteria could enhance surgical quality assessment and inform future guidelines.

研究概览

研究类型

观察性的

注册 (估计的)

120

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients diagnosed of right colon neoplams undergoing elective or emergency surgery.

描述

Inclusion Criteria:

  • The study includes consecuent patients undergoing either elective or emergency surgery with a diagnosis of adenocarcinoma or adenoma with dysplasia located in the cecum, ascending colon, or hepatic flexure of the colon.

Exclusion Criteria:

  • Patients under 18 years of age or lack of informed consent for inclusion in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Patients with right colon neoplasm

pPtients over 18 years of age undergoing either elective or emergency surgery with a diagnosis of adenocarcinoma or adenoma with dysplasia located in the cecum, ascending colon, or hepatic flexure of the colon.

Patients enrolled would receive a right colectomy with dissection of the Lymphoadipose tissue over the superior mesenteric vein, including all the tissue from the ileocolic vessels to the superior right colic vein.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Complete or Incomplete D3L
大体时间:From enrollment to the end of treatment at 8 weeks

Validation of Anatomopathological Criteria for Quality Assessment: to validate, through a multicenter study, the effectiveness of new anatomopathological criteria for right hemicolectomy with D3 lymphadenectomy (D3L) in accurately classifying surgical specimens as complete or incomplete D3L.

From enrollment to the end of treatment at 8 weeks

次要结果测量

结果测量
措施说明
大体时间
Total Number of Lymph Nodes Retrieved
大体时间:From enrollment to the end of treatment at 8 weeks"

To evaluate the total number of lymph nodes retrieved following D3 lymphadenectomy Unit of Measure: Number of lymph nodes

From enrollment to the end of treatment at 8 weeks"
Positive Lymph Nodes Retrieved from the D3 Lymphadenectomy Area
大体时间:From enrollment to the end of treatment at 8 weeks

To determine the presence and number of positive lymph nodes within the D3 lymphadenectomy area.

Unit of Measure: Number of positive lymph nodes

From enrollment to the end of treatment at 8 weeks
Perioperative Complications
大体时间:From enrollment to the end of treatment at 30 days.

To assess the incidence and severity of perioperative complications following right hemicolectomy with D3 lymphadenectomy, according to the Clavien-Dindo classification.

From enrollment to the end of treatment at 30 days.
Local Recurrence
大体时间:From enrollment to the end of treatment at 5 years

To assess the rate of local recurrence following right hemicolectomy with D3 lymphadenectomy.

From enrollment to the end of treatment at 5 years
Systemic Recurrence
大体时间:From enrollment to 5 years

To assess the rate of systemic recurrence following right hemicolectomy with D3 lymphadenectomy.

From enrollment to 5 years
Three-Year Overall Survival
大体时间:From enrollment to 3 years

To assess overall survival at 3 years following right hemicolectomy with D3 lymphadenectomy.

From enrollment to 3 years
Five-Year Overall Survival
大体时间:From enrollment to 5 years

To assess overall survival at 5 years following right hemicolectomy with D3 lymphadenectomy.

From enrollment to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2029年9月30日

研究完成 (估计的)

2031年9月30日

研究注册日期

首次提交

2026年9月23日

首先提交符合 QC 标准的

2026年9月23日

首次发布 (实际的)

2026年9月29日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

No individual participant data (IPD) will be shared because the study was not designed with a data-sharing framework, and the informed consent and ethics approval do not include provisions for public dissemination of participant-level data. To protect participant confidentiality and comply with institutional and regulatory requirements, only aggregated study results will be made available through scientific publications and presentations.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅